Journal of Alzheimers Disease & Parkinsonism
Open Access

Michael Ropacki

Janssen R&D, South San Francisco, CA, USA

Biography

Dr. Michael Ropacki is the President of a San Francisco based consultancy firm, Strategic Global Research & Development (SGR&D) that collaborates with sponsors developing and executing Clinical Development Plans to optimize regulatory interactions. Prior to his role at SGR&D, Dr. Ropacki was most recently Senior Vice President of Clinical Development at MedAvante-ProPhase.

Publications

Alzheimer's and Parkinson's Diseases Face Common Challenges in Therapeutic Development: Role of the Precompetitive Consortium, Coalition Against Major Diseases

Alzheimer’s disease (AD) and Parkinson’s disease (PD) pose significant challenges for successful development of new therapies, with anextremely high drug trial failure rate and yet no approved disease modifying drugs available. Given the magnitude of the challenges, it has become clear that larger collaborations and multi-partner joint ... Read More»

Diane Stephenson, Martha Brumfield, Klaus Romero, Janet Woodcock, Issam Zineh, Eric M Reiman, Caroline Tanner, Richard Mohs, Walter Koroshetz, Timothy Nicholas, Lisa J Bain, Derek Hill, Les Shaw, Johan Luthman, Michael Ropacki, Richard Meibach, Peter Loupos, Ken Marek, James Hendrix, Eric Karran, George Vradenburg, Keiju Motohashi, Jesse M Cedarbaum and Mark Forrest Gordon

Conference Proceeding: J Alzheimers Dis Parkinsonism 2015, 5:183

DOI: 10.4172/2161-0460.1000183

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article